Initial Dose of Three Monthly Intravitreal Injections versus PRN Intravitreal Injections of Bevacizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion

نویسندگان

  • Seong Joon Ahn
  • Jeeyun Ahn
  • Se Joon Woo
  • Kyu Hyung Park
چکیده

PURPOSE To compare visual and anatomic outcomes of intravitreal bevacizumab injections administered as needed (PRN group) and initial treatment with 3 monthly injections followed by as-needed injections (3 monthly initial dose group) in patients with macular edema (ME) secondary to branch retinal vein occlusion (BRVO). METHODS This retrospective study included 69 and 26 patients in the PRN and 3 monthly initial dose groups, respectively. Best-corrected visual acuity (BCVA) and central retinal thickness (CRT) were compared between the 2 groups 6 months after initial injection. RESULTS At month 6, BCVA change from baseline was -0.27 ± 0.28 (mean ± standard deviation) logMAR in the PRN group and -0.28 ± 0.20 logMAR in the 3 monthly initial dose group. Mean CRT changes were -204 ± 168 in the PRN group and -161 ± 149  μ m in the 3 monthly initial dose group at month 6. There were no statistically significant differences in BCVA or CRT changes between groups at any time point. The number of intravitreal injections over 6 months was significantly lower in the PRN group (1.8 ± 0.8 injections) than in the 3 monthly initial dose group (3.4 ± 0.5 injections; P < 0.001). CONCLUSIONS Our results suggest that as-needed intravitreal bevacizumab injections are more tolerable for patients with ME secondary to BRVO.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Outcomes of Intravitreal bevacizumab in patients with acute branch retinal vein occlusion

Introduction: The study aimed to evaluate the long-term effects of intravitreal bevacizumab on macular edema and visual acuity in patients with Acute branch Retinal Vein Occlusion (BRVO) that had not received any treatment. Methods: 22 patients in first week of BRVO onset that was diagnosed with flurcein angiography were treated with intravitreal injection of 1.25 mg bevacizumab. Macular thicke...

متن کامل

Intravitreal bevacizumab (Avastin) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial.

AIMS The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (Avastin) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). METHODS Twenty-nine consecutive eyes with macular oedema secondary to BRVO (21 eyes) or CRVO (eight eyes) were included in a prospective clinical t...

متن کامل

Intravitreal bevacizumab (AvastinH) for macular oedema secondary to retinal vein occlusion: 12-month results of a prospective clinical trial

Accepted 9 November 2008 Published Online First 15 December 2008 ABSTRACT Aims: The aim of the study was to evaluate functional and anatomical changes after intravitreal bevacizumab (AvastinH) in eyes with persistent macular oedema secondary to branch retinal vein occlusion (BRVO) or central retinal vein occlusion (CRVO). Methods: Twenty-nine consecutive eyes with macular oedema secondary to BR...

متن کامل

A 6-month, subject-masked, randomized controlled study to assess efficacy of dexamethasone as an adjunct to bevacizumab compared with bevacizumab alone in the treatment of patients with macular edema due to central or branch retinal vein occlusion

AIMS To determine if intravitreal bevacizumab combined with the dexamethasone intravitreal implant 0.7 mg improves visual acuity and macular thickness more than bevacizumab monotherapy in eyes with macular edema due to branch and central retinal vein occlusions. METHODS Thirty eyes were randomly assigned to receive either combination therapy or bevacizumab monotherapy. All patients received i...

متن کامل

Bevacizumab versus Dexamethasone Implant Followed by Bevacizumab for the Treatment of Macula Edema Associated with Branch Retinal Vein Occlusion

PURPOSE To compare visual and anatomical outcomes of intravitreal injections of bevacizumab and dexamethasone implant (Ozurdex) treatment for macular edema associated with branch retinal vein occlusion (BRVO). METHODS We retrospectively reviewed patients who underwent intravitreal bevacizumab administered monthly on a pro re nata (PRN) basis (26 eyes, IVB group) or an initial 700-μg dexametha...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 2013  شماره 

صفحات  -

تاریخ انتشار 2013